COPD|Inhibitors Agonists Modulators Antagonists|HmoBio.com

Request The Product List ofCOPD COPD

COPD (chronic obstructive pulmonary disease) is a group of lung diseases that make it hard to breathe and get worse over time.

Normally, the airways and air sacs in your lungs are elastic or stretchy. When you breathe in, the airways bring air to the air sacs. The air sacs fill up with air, like a small balloon. When you breathe out, the air sacs deflate, and the air goes out. If you have COPD, less air flows in and out of your airways because of one or more problems:

~The airways and air sacs in your lungs become less elastic

~The walls between many of the air sacs are destroyed

~The walls of the airways become thick and inflamed

~The airways make more mucus than usual and can become clogged

COPD includes two main types:

1.Emphysema affects the air sacs in your lungs, as well as the walls between them. They become damaged and are less elastic.

2.Chronic bronchitis, in which the lining of your airways is constantly irritated and inflamed. This causes the lining to swell and make mucus.

Cat. No.	Product Name	CAS No.	Information
H9329	AZD-5423	1034148-04-3	AZD5423 is an inhaled, potent, selective, and non-steroidal glucocorticoid receptor (GR) modulator (SGRM). AZD5423 effectively reduces allergen-induced responses in subjects with mild allergic asthma.
H8753	Navafenterol	1435519-06-4	Navafenterol a novel inhaled dual M 3 receptor antagonist/β2-adrenoceptor agonist molecule with long-lasting effects and favorable safety profile ;a novel treatment approach to chronic obstructive pulmonary disease [COPD] and potentially also asthma (in combination with an inhaled corticosteroid [ICS]).
H7440	PF-03715455	1056164-52-3	PF-03715455 is a highly potent and selective inhibitor for p38α MAPK with IC50 of 1.6 nM; shows efficacy and safety profiles as an inhaled agent for the treatment of COPD.
H7428	JNJ-49095397	1220626-82-3	JNJ-49095397 (RV-568) is a specific narrow-spectrum kinase inhibitor that inhibits a selected set of kinases involved in COPD inflammation with IC50 of 5, 40 and 52 nM for p38α, p38γ and HCK, respectively; shows potent anti-inflammatory effects in monocytes and macrophages, demonstrates synergistic interaction in poly I:C-stimulated BEAS-2B cells and in the cigarette smoke model combined with corticosteroid.
H7423	AZD-7624	1095004-78-6	AZD-7624 is a potent, selective, inhaled p38α MAPK inhibitor with pIC50 of 10.0, displays 15-fold selectivity for p38α over p38β MAPK and >10,000-fold selectivity over p38γ and p38δ MAPK; inhibits LPS-induced TNF-α and IL-6 release in human alveolar macrophages pIC50 of 9.2 and 8.8, respectively; shows potential for prevention of exacerbations in COPD.
H7087	TG100-115	677297-51-7	A potent, selective PI3Kγ/δ with IC50 of 83/235 nM, respectively; shows no significant inhibitory activity against pI3Kα and β, and a broad panel of kinases (IC50>1 uM); potently inhibits edema and inflammation in response to multiple mediators known to participate in myocardial infarction, such as VEGF and platelet-activating factor, without effect on endothelial cell mitogenesis; provides potent cardioprotection, reduces infarct development and preserves myocardial function in animal MI models.
H7031	GSK-2292767	1254036-66-2	GSK-2269557 is a highly potent and selective inhibitor of PI3Kδ (pKi=10.1); displays >1,000 fold selectivity versus others PI3K isoforms; inhibits both IFNγ and IL-2 production in a concentration-dependent manner, with pIC50 values of 8.7 and 8.5, respectively, in a human lung parenchyma assay; shows activity in rat acute OVA model of Th2-driven lung inflammation (ED50=35 ug/kg).
H7030	GSK-2269557	1254036-71-9	GSK-2269557 is a highly potent and selective inhibitor of PI3Kδ (pKi=9.9); displays >1000 fold selectivity versus other PI3K isoforms; inhibits both IFNγ and IL-2 production in a concentration-dependent manner, with pIC50 values of 8.2 and 8.1, respectively, in a human lung parenchyma assay; shows activity in rat acute OVA model of Th2-driven lung inflammation (ED50=67ug/kg).
H5477	AQX 1125 acetate	782487-29-0	A sepecific, orally bioavailable SHIP1 activator with no effect on functional androgen, oestrogen, oestrogen-related receptor α, glucocorticoid, mineralocorticoid and progesterone receptor at 30 uM; inhibits the pAkt (S473) in MOLT-4 cells, and inhibits cytokine release in mixed splenocytes; significantly decreases β-hexosaminidase release in mouse BMMCs; inhibits chemotaxis in human mononuclear cells (EC50=0.26 uM); suppresses leukocyte accumulation and inflammatory mediator release in rodent models of pulmonary inflammation and allergy.
H5476	AQX 1125	782487-28-9	AQX 1125 (Rosiptor) is a specific, orally bioavailable SHIP1 activator with no effect on functional androgen, oestrogen, oestrogen-related receptor α, glucocorticoid, mineralocorticoid and progesterone receptor at 30 uM; inhibits the pAkt (S473) in MOLT-4 cells, and inhibits cytokine release in mixed splenocytes; significantly decreases β-hexosaminidase release in mouse BMMCs; inhibits chemotaxis in human mononuclear cells (EC50=0.26 uM); suppresses leukocyte accumulation and inflammatory mediator release in rodent models of pulmonary inflammation and allergy.

Select Your Country or Region

Request The Product List ofCOPD COPD

Request The Product List

* Indicates a Required FieldYour information is safe with us.